Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 115

1.

Incidence of skeletal-related events over time from solid tumour bone metastases reported in randomised trials using bone-modifying agents.

Poon M, Zeng L, Zhang L, Lam H, Emmenegger U, Wong E, Bedard G, Lao N, Chow R, Chow E.

Clin Oncol (R Coll Radiol). 2013 Jul;25(7):435-44. doi: 10.1016/j.clon.2013.03.003. Epub 2013 Apr 10. Review.

PMID:
23582277
2.

Bisphosphonates for breast cancer.

Pavlakis N, Schmidt R, Stockler M.

Cochrane Database Syst Rev. 2005 Jul 20;(3):CD003474. Review. Update in: Cochrane Database Syst Rev. 2012;2:CD003474.

PMID:
16034900
3.

Bisphosphonates for breast cancer.

Pavlakis N, Stockler M.

Cochrane Database Syst Rev. 2002;(1):CD003474. Review. Update in: Cochrane Database Syst Rev. 2005;(3):CD003474.

PMID:
11869664
4.

Skeletal-related events (SREs) in breast cancer patients with bone metastases treated in the nontrial setting.

Trinkaus M, Simmons C, Myers J, Dranatisaris G, Clemons M.

Support Care Cancer. 2010 Feb;18(2):197-203. doi: 10.1007/s00520-009-0645-z. Epub 2009 May 8.

PMID:
19424729
5.

Incidence of skeletal morbidity rates over time in patients with multiple myeloma-related bone disease as reported in randomized trials employing bone-modifying agents.

Poon M, Zeng L, Zhang L, Hsiao J, Wong E, Lam H, Bedard G, Chow E.

J Comp Eff Res. 2013 Jan;2(1):69-76. doi: 10.2217/cer.12.69. Review.

PMID:
24236523
6.

Optimal management of metastatic bone disease.

Major P.

Eur J Oncol Nurs. 2007;11 Suppl 2:S32-7. Epub 2007 Sep 4. Review.

PMID:
17804294
7.

Skeletal morbidity rates over time in patients with bone metastases from solid tumors reported in bone modifying agents randomised trials.

Poon M, Zeng L, Zhang L, Popovic M, Chow R, Lam H, Bedard G, Emmenegger U, Simmons C, Chow E.

J Bone Oncol. 2012 Nov 21;1(3):74-80. doi: 10.1016/j.jbo.2012.10.001. eCollection 2012 Dec.

8.

The cost of treatment of skeletal-related events in patients with bone metastases from lung cancer.

Delea T, Langer C, McKiernan J, Liss M, Edelsberg J, Brandman J, Sung J, Raut M, Oster G.

Oncology. 2004;67(5-6):390-6.

PMID:
15713995
9.

Bone-targeted therapy use in patients with bone metastases from lung cancer: A systematic review of randomized controlled trials.

LeVasseur N, Clemons M, Hutton B, Shorr R, Jacobs C.

Cancer Treat Rev. 2016 Nov;50:183-193. doi: 10.1016/j.ctrv.2016.09.013. Epub 2016 Sep 20. Review.

PMID:
27716496
10.

Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States.

Stopeck A, Rader M, Henry D, Danese M, Halperin M, Cong Z, Qian Y, Dansey R, Chung K.

J Med Econ. 2012;15(4):712-23. doi: 10.3111/13696998.2012.675380. Epub 2012 Mar 27.

PMID:
22409231
11.

Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases.

Ibrahim A, Scher N, Williams G, Sridhara R, Li N, Chen G, Leighton J, Booth B, Gobburu JV, Rahman A, Hsieh Y, Wood R, Vause D, Pazdur R.

Clin Cancer Res. 2003 Jul;9(7):2394-9.

12.
13.

Clinical benefit of zoledronic acid in patients with lung cancer and other solid tumors: analysis based on history of skeletal complications.

Hirsh V, Tchekmedyian NS, Rosen LS, Zheng M, Hei YJ.

Clin Lung Cancer. 2004 Nov;6(3):170-4.

PMID:
15555218
14.

Efficacy and safety of zoledronic acid in patients with breast cancer metastatic to bone: a multicenter clinical trial.

Cartenì G, Bordonaro R, Giotta F, Lorusso V, Scalone S, Vinaccia V, Rondena R, Amadori D.

Oncologist. 2006 Jul-Aug;11(7):841-8.

15.

Retrospective study of the effect of skeletal complications on total medical care costs in patients with bone metastases of breast cancer seen in typical clinical practice.

Delea T, McKiernan J, Brandman J, Edelsberg J, Sung J, Raut M, Oster G.

J Support Oncol. 2006 Jul-Aug;4(7):341-7.

PMID:
16892696
16.

Zoledronate for metastatic bone disease and pain: a meta-analysis of randomized clinical trials.

Zhu M, Liang R, Pan LH, Huang B, Qian W, Zhong JH, Zheng WW, Li CL.

Pain Med. 2013 Feb;14(2):257-64. doi: 10.1111/pme.12016. Epub 2012 Dec 28.

PMID:
23279447
18.

Risk Factors for Developing Skeletal-Related Events in Breast Cancer Patients With Bone Metastases Undergoing Treatment With Bone-Modifying Agents.

Tanaka R, Yonemori K, Hirakawa A, Kinoshita F, Takahashi N, Hashimoto J, Kodaira M, Yamamoto H, Yunokawa M, Shimizu C, Fujimoto M, Fujiwara Y, Tamura K.

Oncologist. 2016 Apr;21(4):508-13. doi: 10.1634/theoncologist.2015-0377. Epub 2016 Mar 14.

19.

Efficacy of clodronate, pamidronate, and zoledronate in reducing morbidity and mortality in cancer patients with bone metastasis: a meta-analysis of randomized clinical trials.

Machado M, Cruz LS, Tannus G, Fonseca M.

Clin Ther. 2009 May;31(5):962-79. doi: 10.1016/j.clinthera.2009.05.009. Review.

PMID:
19539097
20.

Skeletal-related events in advanced lung adenocarcinoma patients evaluated EGFR mutations.

Nagata M, Kudoh S, Mitsuoka S, Suzumura T, Umekawa K, Tanaka H, Matsuura K, Kimura T, Yoshimura N, Hirata K.

Osaka City Med J. 2013 Jun;59(1):45-52.

PMID:
23909080

Supplemental Content

Support Center